TrialBlood2011

Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results.

Hagop M Kantarjian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.